Materials and methods: The immunoscore (CD3 and CD8) was performed on 331 well characterized CRC patients including the TNM classification, L and V stage, perineuronal infiltration, histological subtype, tumor grade, peritumoral inflammation, mismatch repair status, overall survival and information on adjuvant radio- and chemotherapy using the Roche Benchmark II Ultra and the Definiens Software for the digital pathology analysis. This evidence concerns the gene CD8A and neoplasm.